Top Markets
Coin of the day
Lexaria Bioscience Corp. Lexaria Bioscience Corp.

Lexaria Bioscience Corp.

LEXXW
Pozycja w akcjach #41277
Lexaria Bioscience Corp. is a biotechnology firm specializing in the creation... Lexaria Bioscience Corp. is a biotechnology firm specializing in the creation and licensing of its patented drug delivery system, DehydraTECH. This innovative technology functions by integrating fat-soluble compounds or active pharmaceutical ingredients (APIs) with particular long-chain fatty acids and specific carrier substances. The aim of this process is to significantly boost their entry into the bloodstream, consequently enhancing their effectiveness, enabling lower overall dosages, and supporting healthier methods of oral consumption. DehydraTECH can be utilized with a broad spectrum of active molecules, including fat-soluble vitamins, pain relievers, hormones, PDE5 inhibitors, antiviral agents, oral nicotine and its analogues, and various cannabinoids. The company is also investigating DehydraTECH's potential therapeutic applications for conditions such as high blood pressure, cardiovascular diseases, and diabetes. Its versatility renders it suitable for integration into diverse product categories, encompassing pharmaceuticals, nutraceuticals, over-the-counter remedies, and consumer packaged goods. Established in 2004, Lexaria Bioscience Corp. is headquartered in Kelowna, Canada.
Cena akcji
$0.0012
Ostatnia synchronizacja: 2026-01-13
Kapitalizacja rynkowa
$29.83K
Zmiana (1 dzień)
-77.36%
Zmiana (1 rok)
-98.91%
Kraj
US
Handel Lexaria Bioscience Corp. (LEXXW)

Kategoria

EPS dla Lexaria Bioscience Corp. (LEXXW)
EPS na dzień 2026 TTM: 0
Według najnowszych raportów finansowych i ceny akcji firmy Lexaria Bioscience Corp., obecny EPS (TTM) wynosi 0. Na koniec roku 2026 firma miała EPS w wysokości 0, równa się do EPS z roku 2026, który wynosił 0.
Historia EPS dla Lexaria Bioscience Corp. od 2026 do 2026
EPS na koniec każdego roku
Rok EPS Zmień
Za mało danych dla podanych dat.
EPS dla podobnych firm lub konkurentów